Meg shares why she dropped the protein shakes she relied on while taking tirzepatide. Her reasons are her own experience, not medical advice.
Recap by typeshit. Full story at Millennial Meg’s Health Spot.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
Icotrokinra became the first approved oral IL23 receptor blocker, and a trial found tirzepatide plus ixekizumab gave deeper responses.
Oral Wegovy fell to about 173,500 weekly prescriptions and Foundayo rose to 60,151. Novo also eyes 15 to 20% yearly GLP-1 growth in India.
Loading…